Prime Medicine, Inc.

NasdaqGM PRME

Prime Medicine, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2024: USD 0.00

Prime Medicine, Inc. Dividends Paid is USD 0.00 for the Trailing 12 Months (TTM) ending September 30, 2024, a 0.00% change year over year. Dividends paid is cash paid to shareholders as a distribution of profits.

Prime Medicine, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2023 was USD 0.00, a 0.00% change year over year.
Prime Medicine, Inc. Dividends Paid for the Trailing 12 Months (TTM) ending September 30, 2022 was USD 0.00.

Key data

Date	Dividends Paid	Capital Expenditure	Other Financing Activities	Net Cash Used Provided By Financing Activities

NasdaqGM: PRME

Prime Medicine, Inc.

CEO	Dr. Keith Michael Gottesdiener M.D., Ph.D.
IPO Date	Oct. 20, 2022
Location	United States
Headquarters	21 Erie Street
Employees	234
Sector	Healthcare
Industries Biotechnology

Description

Prime Medicine, Inc., a biotechnology company, delivers genetic therapies to address diseases by deploying gene editing technology. It offers Prime Editors with a Prime Editor protein, comprising a fusion between a Cas protein and a reverse transcriptase enzyme; and a pegRNA, which targets the Prime Editor to a specific genomic location and provides a template for making the desired edit to the target DNA sequence. The company was incorporated in 2019 and is headquartered in Cambridge, Massachusetts.

Key trends

Past 5 years